0001127602-24-012708.txt : 20240409
0001127602-24-012708.hdr.sgml : 20240409
20240409160904
ACCESSION NUMBER: 0001127602-24-012708
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240405
FILED AS OF DATE: 20240409
DATE AS OF CHANGE: 20240409
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mock James M
CENTRAL INDEX KEY: 0001736359
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 24832807
MAIL ADDRESS:
STREET 1: 940 WINTER STREET
STREET 2: PERKINELMER
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 325 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 325 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-04-05
0001682852
Moderna, Inc.
MRNA
0001736359
Mock James M
325 BINNEY STREET
CAMBRIDGE
MA
02142
1
Chief Financial Officer
1
Common Stock
2024-04-05
4
M
0
1453
A
5753
D
Common Stock
2024-04-08
4
S
0
705
101.9281
D
5048
D
Restricted Stock Units
2024-04-05
4
M
0
1453
0
D
Common Stock
1453
14527
D
Restricted stock units convert into common stock on a one-for-one basis.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
25% of the shares subject to this restricted stock unit award vested on October 5, 2023 with the remainder vesting in twelve (12) equal quarterly installments thereafter.
/s/ James Dillon, As Attorney-in-Fact
2024-04-09